Skip to Content
Diagnosed with ankylosing spondylitis? Biologics can help >>

Anturane (sulfinpyrazone) Disease Interactions

There are 4 disease interactions with Anturane (sulfinpyrazone):

Major

Sulfinpyrazone (Includes Anturane) ↔ Blood Dyscrasias

Severe Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts, Anemia, History - Blood Dyscrasias

The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias. Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use. Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia. Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.

References

  1. "Multum Information Services, Inc. Expert Review Panel"
  2. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  3. "Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals, East Hanover, NJ.
Major

Sulfinpyrazone (Includes Anturane) ↔ Upper Gi Irritation

Severe Potential Hazard, High plausibility

Applies to: Peptic Ulcer, History - Peptic Ulcer, Duodenitis/Gastritis with Hemorrhage, Duodenitis/Gastritis

The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration. Sulfinpyrazone may commonly cause upper gastrointestinal irritation. It may also aggravate or reactivate peptic ulcer. Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer. Taking the medication with food, milk, or antacids may lessen GI adverse effects.

References

  1. "Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals, East Hanover, NJ.
Moderate

Sulfinpyrazone (Includes Anturane) ↔ Dehydration

Moderate Potential Hazard, High plausibility

Applies to: Dehydration, Diarrhea, Vomiting

Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.

References

  1. "Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals, East Hanover, NJ.
Moderate

Sulfinpyrazone (Includes Anturane) ↔ Renal Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Renal failure has occasionally been reported with the use of sulfinpyrazone. Therapy with sulfinpyrazone should be administered cautiously in patients with significant renal impairment. Adequate hydration and periodic monitoring of renal function are recommended.

References

  1. "Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals, East Hanover, NJ.

Anturane (sulfinpyrazone) drug Interactions

There are 525 drug interactions with Anturane (sulfinpyrazone)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide